Blood-soluble Fas Levels are Increased in Type 2 Diabetic Patients with Peripheral Vascular Disease (original) (raw)

Horm Metab Res 2006; 38(10): 673-677
DOI: 10.1055/s-2006-954585

Original Clinical

M. T. García-Unzueta 1 , C. Pesquera 1 , E. Calzada 2 , A. De la Mora 3 , P. Muñoz 4 , J. Llorca 5 , N. Morchón 6 , M. D. Fernández-González 6 , J. A. Amado 1

1Endocrinology Services, Hospital Universitario “Marqués de Valdecilla”, Universidad de Cantabria, Santander, Spain
2Primary Care Physician, Servicio Cántabro de Salud, Spain
3Ophthalmology Service, Hospital Sierrallana, Torrelavega, Spain
4Public Health Technic, Servicio Cántabro de Salud, Santander, Spain
5Epidemiology and Public Health Professor, Universidad de Cantabria, Santander, Spain
6Clinical Biochemistry Services, Hospital Universitario “Marqués de Valdecilla”, Universidad de Cantabria, Santander, Spain

Further Information

Publication History

Received 28 November 2005

Accepted after revision 6 June 2006

Publication Date:
30 October 2006 (online)

Abstract

Aim: To investigate the possible utility of plasma sFas (soluble Fas) levels as a marker of peripheral vascular disease (PVD) in type 2 diabetic patients, and the relationship between classical cardiovascular risk factors and sFas levels in these patients. Materials and Methods: sFas levels were measured in 57 type 2 diabetic patients with and 60 without PVD matched for age and sex. Diagnosis of PVD was established in presence of at least one of the following criteria: leg or foot amputation of vascular cause, lower-extremity arterial angioplasty or surgical by-pass, or ankle-braquial index (ABI) less than 1 in at least one side of the body. ELISA was used to measure sFas levels. Results: None of the risk factors assessed total cholesterol, HDL cholesterol, triglycerides, CRP, ACE, fibrinogen, Lp(a) and homocysteine was significantly different between both groups of patients. However, patients with PVD had higher plasma sFas levels than the group without PVD (10.25±3.7 ng/ml vs. 8.86±2.6 ng/ml; p=0.02). Levels of sFas were 1.45 ng/ml (95% CI: 0.32-2.58; p=0.013) higher in PVD patients when adjusting by age, total, HDL and LDL cholesterol, triglycerides, homocysteine, CRP, ACE, arterial hypertension and tobacco smoking. Using multiple logistic regression sFas is a predictor of PVD, although not potent. Conclusion: Plasma sFas may be an independent marker of PVD in type 2 diabetes mellitus patients.

Key words

sFas - vascular disease - diabetes mellitus - cardiovascular risk factors

References

1 Maser RE, Wolfson Jr SK, Ellis D, Stein EA, Drash AL, Becker DJ, Dorman JS, Orchard TJ. Cardiovascular disease and arterial calcification in insulin-dependent diabetes mellitus: Interactions and risk factors profiles. Pittsburg Epidemiology of Diabetes Complications Study (V). Arterioscl Thromb. 1991; 11 958-965
2 Almdal T, Scharling H, Jensen JS, Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med. 2004; 164 1422-1426
3 Meigs JB. Epidemiology of cardiovascular complications in type 2 diabetes mellitus. Acta Diabetol. 2003; 40 ((Suppl 2)) S358-S361
4 Fisher M. Diabetes and atherogenesis. Heart. 2004; 90 336-340
5 Berry J, Keebler ME, McGuire DK. Diabetes Mellitus and cardiovascular disease. Pandora's box has been opened. Herz. 2004; 29 456-462
6 Nagata S. Apoptosis by death factor. Cell. 1997; 88 355-365
7 Kockx M. Apoptosis in the atherosclerotic plaque: quantitative and qualitative aspects. Arterioscler Thromb Vasc Biol. 1998; 18 1519-1522
8 Schneider DB, Vasalli G, Wen S, Driscoll RM, Sassani AB, DeYoung MB, Linnemann R, Virmani R, Dichek DA. Expression of Fas ligand in arteries of hypercholesterolemic rabbits accelerates atherosclerotic lesion formation. Arterioscler Thromb Vasc Biol. 2000; 20 298-308
9 Cai W, Devaux B, Schaper W, Schaper J. The role of Fas/APO1 and apoptosis in the development of human atherosclerotic lesions. Atherosclerosis. 1997; 131 177-186
10 Granville DJ, Carthy CM, Hunt DWC, Mc Manus BM. Apoptosis: molecular aspects of cell death and disease. Lab Invest. 1998; 78 893-913
11 Nagata S. Fas anf Fas ligand: a death factor and its receptor. Adv Inmunol. 1994; 57 129-144
12 Nagata S, Golstein P. The Fas death factor. Science. 1995; 267 1449-1456
13 Cascino I, Papoff G, Eramo A, Ruberti G. Soluble Fas/APO-1 splicing variants and apoptosis. Frontiers Biosci. 1996; 1 12-18
14 Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, Motoyoshi K, Mizuki M, Tagawa S, Ohga S, Hatake K, Drummond AH, Nagata S. Fas ligand in human serum. Nat Med. 1996; 2 317-322
15 Buzas K, Megyeri K, Hogye M, Csanady M, Bogats G, Mandi Y. Comparative study of the roles of cytokines and apoptosis in dilated and hypertrophic cardiomyopathies. Eur Cytokine Netw. 2004; 15 53-59
16 Li Y, Takemura G, Kosai K, Takahashi T, Okada H, Miyata S, Yuge K, Nagano S, Esaki M, Khai NC, Goto K, Mikami A, Maruyama R, Minatoguchi S, Fujiwara T, Fujiwara H. Critical roles for the Fas/Fas ligand system in postinfarction ventricular remodelling and heart failure. Circulation Res. 2004; 95 627-636
17 Fiorina P, Astorri E, Albertini R, Secchi A, Mello A, Lanfredini M, Creveri A, Olivetti G, Quaini F. Soluble antiapoptotic molecules and immune activation in chronic heart failure and unstable angina pectoris. J Clin Immunol. 2000; 20 101-106
18 Christensson M, Pettersson E, Eneslatt K, Christensson B, Bratt J, Rantapaa-Dahlqvist S, Sundqvist KG. Serum sFas levels are elevated in ANCA-positive vasculitis compared with other autoimmune diseases. J Clin Inmunol. 2002; 22 220-227
19 Troyanov S, Hebert MJ, Masse M, Vigneault N, Sirois I, Madore F. Soluble Fas: a novel predictor of atherosclerosis in dialysis patients. Am J Kidney Dis. 2003; 41 1043-1051
20 Dalboni MA, Sardenberg C, Andreoli MC, Watanabe R, Canziani ME, Santos BF, Liangos O, Jaber BL, Draibe S, Cendoroglo M. Soluble Fas: a novel marker of inflammation in uremia. Artif Organs. 2003; 27 687-691
21 Sato M, Konuma T, Yanagisawa N, Haizuka H, Asakura H, Nakashima Y. Fas-Fas ligand system in the peripheral blood of patients with renal diseases. Nephron. 2000; 85 107-113
22 Masse M, Hébert MJ, Troyanov S, Vigneault N, Sirois I, Madore F. Soluble Fas is a marker of peripheral arterial occlusive disease in haemodialysis patients. Nephrol Dial Transplant. 2002; 17 485-491
23 Guillot R, Bringuier AF, Porokhov B, Guillausseau PJ, Feldmann G. Increased levels of soluble Fas in serum from diabetic patients with neuropathy. Diabetes Metab. 2001; 27 315-321
24 Baba K, Manitoguchi S, Sano H, Kagawa T, Murata I, Takemura G, Hirano T, Ohashi H, Takemura M, Fujiwara T, Fujiwara H. Involvement of apoptosis in patients with diabetic nephropathy: a study on plasma soluble Fas levels and pathological findings. Nephrology. 2004; 9 94-99
25 Amado JA, Calzada E, García-Unzueta MT, de la Mora A, Muñoz P. Prevalencia de arteriopatía periférica valorada por Doppler en pacientes con diabetes mellitus tipo 2 de Cantabria. Endocrinol Nutr. 2001; 48 ((Suppl 2)) 27
26 Apelqvist J, Castenfors J, Stenström A, Agardh CD. Prognostic value of systolic ankle and toe blood pressure levels in outcome of diabetic foot ulcer. Diabetes Care. 1989; 12 373-378
27 Wang T, Dong C, Stevenson SC, Herderick EE, Marshall-Neff J, Vasudevan SS, Moldovan NI, Michler RE, Movva NR, Goldschmidt-Clermont PJ. Overexpression of soluble Fas attenuates transplant arteriosclerosis in rat aortic allografts. Circulation. 2002; 106 1536-1542
28 Hébert MJ, Masse M, Vigneault N, Sirois I, Troyanov S, Madore F. Soluble Fas is a marker of coronary artery disease in patients with end-stage renal disease. Am J Kidney Dis. 2001; 38 1271-1276
29 Van der Meer IM, Oei HHS, Hofman A, Pols HAP, de Jong FH, Witteman JCM. Soluble Fas, a mediator of apoptosis, C-reactive protein, and coronary and extracoronary atherosclerosis. The Rotterdam Coronary Calcification Study. Atherosclerosis (in press). 2006;
30 Cosson E, Bringuier AF, Paries J, Guillot R, Vaysse J, Attali JR, Feldmann G, Valensi P. Fas/Fas-Ligand pathway is impaired in patients with type 2 diabetes. Influence of hypertension and insulin resistance. Diabetes Metab. 2005; 31 47-54

Correspondence

M. T. García-Unzueta

Endocrine Unit·Hospital Universitario M. de Valdecilla

Valdecilla Street

39008 Santander

Spain

Phone: +34/42/20 16 63

Fax: +34/42/20 16 63

Email: mgunzueta@humv.es